Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.

Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy and the safety of cemiplimab in a real-world clinical setting.

Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?

Purpose: To review the experiences regarding the therapeutic response and side effects of concomitant radiochemotherapy of cervical cancer carried out with different cisplatin doses.

Patients And Methods: At the Municipal Center for Oncoradiology, Budapest, Hungary, 92 patients with cervical cancer were treated with concomitant radiochemotherapy in the period between July 2002 and March 2007. The total dose of high-energy external radiation (megavoltage) treatment was 50.

[Experience with only preoperative radiotherapy of non-metastatic rectal tumours].

Introduction: It is an accepted fact that the local recurrence rate can be decreased up to 50% for the metastatic rectum tumours irradiated only preoperatively.

Materials And Methods: 181 patients having rectum tumour were irradiated preoperatively with 36 or 40 Gy between 1990 and 2001. The classification was made according to the modified Astler-Coller pathological staging system.

[Radiochemotherapy of cervical carcinoma. (Necessity of dose reduction in chemotherapy)].

Introduction: The concurrent radiochemotherapy used in the treatment of high risk and locally advanced cervical cancer therapy seems to be standard practice. Studies carried out in 1999 and 2000, reported the results of five large-scale prospective randomized investigations using radiotherapy which showed progression-free and overall survival rate increase compared to use of solely radiotherapy (Gynecology Oncology Group (GOG) 123, South West Oncology Group (SWOG) 8797, Radiotherapy Oncology Group (RTOG) 9001, Gynecology Oncology Group (GOG) 85, Gynecology Oncology Group (GOG) 120).

Objectives: The aim of the investigation was to report our early findings of cervical cancer radiotherapy detailing the arising radiogen toxicity.

Perioperative brachytherapy for pretreated chest wall recurrence of breast cancer.

Purpose: To demonstrate the technical aspects of high-dose-rate afterloading (HDR-AL) brachytherapy for isolated local chest wall recurrence of breast cancer pretreated with mastectomy and axillary node dissection plus postoperative radiotherapy.

Case Report: A 63-year-old female patient with left ductal breast cancer, pT2pN1biM0, was reoperated for an isolated local chest wall recurrence 13 years after primary treatment (mastectomy, axillary dissection, and 50 Gy postoperative irradiation). Radical surgery would have involved extreme mutilation.

Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up.

In the period between 1959 and 1980 165 patients previously operated with ovarian tumor were treated by intraperitoneally administered (198)Au in the Oncoradiological Centre of the Uzsoki Hospital. The stage distribution of the 158 patients with common epithelial histology was as it follows: Stage I/A 31; Stage I/B 9; Stage I/C 59; Stage II/A 19; Stage II/B 11; Stage II/C 7, Stage III/A 22. The five year survival result is the next: Stage I/A 90%; Stage I/B 78%; Stage I/C 58%; Stage II/A 26%; Stage II/B 27%; Stage II/C 14%; Stage III/A 18%.

Early Experiences with Combined Treatment (Surgery and Brachytherapy) of Gynecological Recurrences Infiltrating the Pelvic Wall.

Neither the surgical nor the radiotherapeutic treatment of gynecological recurrences infiltrating the pelvic wall can be curative alone. The treatment of this group of patients is possible with the CORT (Combined Operative and Radiotherapeutic Treatment) method. As maximal as possible resection of the malignancy is done for patients having no distant metastases and the brachytherapy guiding tubes are implanted into the tumour bed on the pelvic wall.